Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat
- PMID: 2934513
- DOI: 10.1007/BF01245975
Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat
Abstract
Chronic oral treatment (8 weeks) with the selective 5-hydroxytryptamine2 (5-HT2)-receptor blocking agent, ritanserin, did not reduce blood pressure in the spontaneously hypertensive rat (SHR) during basal conditions or during stress (jet air). In pithed rats the pressor responses to 5-HT but not to phenylephrine or sympathetic stimulation of the sympathetic outflow were completely antagonized. These observations indirectly suggests that the 5-HT2-receptor blocking properties of the antihypertensive agent ketanserin cannot alone account for the antihypertensive effects in SHR that are observed during chronic treatment with this agent.
Similar articles
-
Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.J Cardiovasc Pharmacol. 1988;11 Suppl 1:S22-4. J Cardiovasc Pharmacol. 1988. PMID: 2459509
-
Antihypertensive effects of ketanserin in the spontaneously hypertensive rat: mode of action.J Cardiovasc Pharmacol. 1985;7 Suppl 7:S110-1. doi: 10.1097/00005344-198500077-00031. J Cardiovasc Pharmacol. 1985. PMID: 2412026
-
Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat.Naunyn Schmiedebergs Arch Pharmacol. 1985 Jun;329(4):394-7. doi: 10.1007/BF00496374. Naunyn Schmiedebergs Arch Pharmacol. 1985. PMID: 2993926
-
Interference of ketanserin with baroreflex control of the circulation in the conscious spontaneously hypertensive rat.Drugs. 1988;36 Suppl 1:55-60. doi: 10.2165/00003495-198800361-00009. Drugs. 1988. PMID: 3149239
-
Antihypertensive mode of action of ketanserin.J Cardiovasc Pharmacol. 1987;10 Suppl 3:S45-7. J Cardiovasc Pharmacol. 1987. PMID: 2446069 Review.
Cited by
-
Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.Eur J Clin Pharmacol. 1993;44(2):121-5. doi: 10.1007/BF00315468. Eur J Clin Pharmacol. 1993. PMID: 8453957
-
5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.Cardiovasc Ther. 2011 Feb;29(1):54-67. doi: 10.1111/j.1755-5922.2010.00173.x. Cardiovasc Ther. 2011. PMID: 20433685 Free PMC article. Review.
-
Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.Drugs. 1990 Dec;40(6):903-49. doi: 10.2165/00003495-199040060-00010. Drugs. 1990. PMID: 2079001 Review.
-
Cardiovascular effects of intrathecal administration of substance P in the rat: interactions with serotonergic mechanisms.J Neural Transm Gen Sect. 1992;87(3):199-213. doi: 10.1007/BF01245366. J Neural Transm Gen Sect. 1992. PMID: 1374613
-
Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).Am J Physiol Heart Circ Physiol. 2016 Nov 1;311(5):H1225-H1233. doi: 10.1152/ajpheart.00538.2016. Epub 2016 Sep 23. Am J Physiol Heart Circ Physiol. 2016. PMID: 27663771 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical